Silvia Parolini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8123549/publications.pdf

Version: 2024-02-01

64 papers	6,423 citations	109321 35 h-index	114465 63 g-index
65 all docs	65 docs citations	65 times ranked	7332 citing authors

#	Article	IF	Citations
1	Lack of DOCK8 impairs the primary biologic functions of human NK cells and abrogates CCR7 surface expression in a WASP-independent manner. Clinical Immunology, 2022, 237, 108974.	3.2	2
2	Combined immunodeficiency with autoimmunity caused by a homozygous missense mutation in inhibitor of nuclear factor ?B kinase alpha (IKKÎ±). Science Immunology, 2021, 6, eabf6723.	11.9	6
3	Natural killer cell impairment in ovarian clear cell carcinoma. Journal of Leukocyte Biology, 2020, 108, 1425-1434.	3.3	3
4	From Natural Killer Cell Receptor Discovery to Characterization of Natural Killer Cell Defects in Primary Immunodeficiencies. Frontiers in Immunology, 2019, 10, 1757.	4.8	2
5	The RAC2-PI3K axis regulates human NK cell maturation and function. Clinical Immunology, 2019, 208, 108257.	3.2	11
6	Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 890.	4.1	34
7	A monoallelic activating mutation in RAC2 resulting in a combined immunodeficiency. Journal of Allergy and Clinical Immunology, 2019, 143, 1649-1653.e3.	2.9	37
8	In vitro treatment with concentrated growth factors (CGF) and sodium orthosilicate positively affects cell renewal in three different human cell lines. Cell Biology International, 2018, 42, 353-364.	3.0	22
9	CTLA-4 regulates human Natural Killer cell effector functions. Clinical Immunology, 2018, 194, 43-45.	3.2	30
10	Response to the Letter to the Editor Regarding â€œFunctional evaluation of natural killer cell cytotoxic activity in NFKB-2 mutated patientsâ€• Immunology Letters, 2018, 200, 16-17.	2.5	0
11	Identification of a subset of human natural killer cells expressing high levels of programmed death 1: AÂphenotypic and functional characterization. Journal of Allergy and Clinical Immunology, 2017, 139, 335-346.e3.	2.9	379
12	Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations. Journal of Allergy and Clinical Immunology, 2017, 140, 553-564.e4.	2.9	58
13	NFKB1 regulates human NK cell maturation and effector functions. Clinical Immunology, 2017, 175, 99-108.	3.2	38
14	Natural Killer Cells from Patients with Recombinase-Activating Gene and Non-Homologous End Joining Gene Defects Comprise a Higher Frequency of CD56bright NKG2A+++ Cells, and Yet Display Increased Degranulation and Higher Perforin Content. Frontiers in Immunology, 2017, 8, 798.	4.8	41
15	p85Î± is an intrinsic regulator of human natural killer cell effector functions. Journal of Allergy and Clinical Immunology, 2016, 138, 605-608.e3.	2.9	7
16	Natural killer cell hyporesponsiveness and impaired development in a CD247-deficient patient. Journal of Allergy and Clinical Immunology, 2016, 137, 942-945.e4.	2.9	12
17	Pseudorabies Virus US3 Protein Kinase Protects Infected Cells from NK Cell-Mediated Lysis via Increased Binding of the Inhibitory NK Cell Receptor CD300a. Journal of Virology, 2016, 90, 1522-1533.	3.4	26
18	Inherited DOCK2 Deficiency in Patients with Early-Onset Invasive Infections. New England Journal of Medicine, 2015, 372, 2409-2422.	27.0	169

#	Article	IF	Citations
19	Defective natural killerâ€“cell cytotoxic activity in NFKB2-mutated CVID-like disease. Journal of Allergy and Clinical Immunology, 2015, 135, 1641-1643.e3.	2.9	68
20	B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. OncoImmunology, 2015, 4, e1001224.	4.6	137
21	Primitive Neuroectodermal Tumor in an Ovarian Cystic Teratoma: Natural Killer and Neuroblastoma Cell Analysis. Case Reports in Oncology, 2014, 7, 70-78.	0.7	12
22	Effects of opioid therapy on human natural killer cells. International Immunopharmacology, 2014, 18, 169-174.	3.8	24
23	<scp>XLP</scp>1 inhibitory effect by 2<scp>B</scp>4 does not affect <scp>DNAM</scp>â€1 and <scp>NKG</scp>2<scp>D</scp> activating pathways in <scp>NK</scp> cells. European Journal of Immunology, 2014, 44, 1526-1534.	2.9	20
24	Activin A as a Mediator of NKâ€“Dendritic Cell Functional Interactions. Journal of Immunology, 2014, 192, 1241-1248.	0.8	27
25	Diagnosing XLP1 in patients with hemophagocytic lymphohistiocytosis. Journal of Allergy and Clinical Immunology, 2014, 134, 1381-1387.e7.	2.9	14
26	Clinical, laboratory and molecular signs of immunodeficiency in patients with partial oculo-cutaneous albinism. Orphanet Journal of Rare Diseases, 2013, 8, 168.	2.7	70
27	Occurrence of Nodular Lymphocyte-Predominant Hodgkin Lymphoma in Hermansky-Pudlak Type 2 Syndrome Is Associated to Natural Killer and Natural Killer T Cell Defects. PLoS ONE, 2013, 8, e80131.	2.5	34
28	A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. Journal of Experimental Medicine, 2012, 209, 29-34.	8.5	158
29	Exome sequencing reveals a pallidin mutation in a Hermansky-Pudlakâ€“like primary immunodeficiency syndrome. Blood, 2012, 119, 3185-3187.	1.4	76
30	A novel primary human immunodeficiency due to deficiency in the WASP-interacting protein WIP. Journal of Cell Biology, 2012, 196, i1-i1.	5.2	0
31	NK cells and their receptors during viral infections. Immunotherapy, 2011, 3, 1075-1086.	2.0	25
32	Severe impairment of IFN-Î³ and IFN-Î± responses in cells of a patient with a novel STAT1 splicing mutation. Blood, 2011, 118, 1806-1817.	1.4	84
33	GPR56 as a novel marker identifying the CD56dull CD16+ NK cell subset both in blood stream and in inflamed peripheral tissues. International Immunology, 2010, 22, 91-100.	4.0	33
34	NK cells at the interface between innate and adaptive immunity. Cell Death and Differentiation, 2008, 15, 226-233.	11.2	291
35	The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood, 2007, 109, 3625-3632.	1.4	336
36	Functional characterization of natural killer cells in type I leukocyte adhesion deficiency. Blood, 2007, 109, 4873-4881.	1.4	29

#	Article	IF	Citations
37	Novel insights from adaptor protein 3 complexÂdeficiency. Journal of Allergy and Clinical Immunology, 2007, 120, 735-741.	2.9	51
38	Innate immunity defects in Hermansky-Pudlak type 2 syndrome. Blood, 2006, 107, 4857-4864.	1.4	136
39	Reduced thymic output, increased spontaneous apoptosis and oligoclonal B cells in polyethylene glycol-adenosine deaminase-treated patients. European Journal of Immunology, 2005, 35, 3376-3386.	2.9	59
40	Distinctive Lack of CD48 Expression in Subsets of Human Dendritic Cells Tunes NK Cell Activation. Journal of Immunology, 2005, 175, 3690-3697.	0.8	26
41	IL-12 or IL-4 Prime Human NK Cells to Mediate Functionally Divergent Interactions with Dendritic Cells or Tumors. Journal of Immunology, 2005, 174, 3992-3998.	0.8	117
42	Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood, 2004, 104, 436-443.	1.4	130
43	Selective cross-talk among natural cytotoxicity receptors in human natural killer cells. European Journal of Immunology, 2003, 33, 1235-1241.	2.9	77
44	CD59 is physically and functionally associated with natural cytotoxicity receptors and activates human NK cell-mediated cytotoxicity. European Journal of Immunology, 2003, 33, 3367-3376.	2.9	77
45	IL-21 induces both rapid maturation of human CD34+ cell precursors towards NK cells and acquisition of surface killer Ig-like receptors. European Journal of Immunology, 2003, 33, 3439-3447.	2.9	166
46	Killer cell immunoglobulin-like receptor expression delineatesin situSÃ©zary syndrome lymphocytes. Journal of Pathology, 2003, 199, 77-83.	4.5	47
47	Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 4526-4531.	7.1	174
48	Cellular and molecular pathogenesis of X-linked lymphoproliferative disease. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 513-517.	2.3	7
49	Human natural killer cell receptors and coâ€receptors. Immunological Reviews, 2001, 181, 203-214.	6.0	273
50	Identification of NKp80, a novel triggering molecule expressed by human NK cells. European Journal of Immunology, 2001, 31, 233-242.	2.9	185
51	Gntb-A, a Novel Sh2d1a-Associated Surface Molecule Contributing to the Inability of Natural Killer Cells to Kill Epstein-Barr Virusâ€“Infected B Cells in X-Linked Lymphoproliferative Disease. Journal of Experimental Medicine, 2001, 194, 235-246.	8.5	287
52	X-linked lymphoproliferative disease: the dark side of 2b4 function. Advances in Experimental Medicine and Biology, 2001, 495, 63-67.	1.6	3
53	2B4 functions as a co-receptor in human NK cell activation. European Journal of Immunology, 2000, 30, 787-793.	2.9	202
54	Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines. Journal of Neuroimmunology, 2000, 107, 220-225.	2.3	103

#	Article	IF	Citations
55	X-Linked Lymphoproliferative Disease. Journal of Experimental Medicine, 2000, 192, 337-346.	8.5	438
56	Triggering receptors involved in natural killer cell-mediated cytotoxicity against choriocarcinoma cell lines. Human Immunology, 2000, 61, 1055-1058.	2.4	71
57	Identification and Molecular Characterization of Nkp30, a Novel Triggering Receptor Involved in Natural Cytotoxicity Mediated by Human Natural Killer Cells. Journal of Experimental Medicine, 1999, 190, 1505-1516.	8.5	664
58	NKp44, A Triggering Receptor Involved in Tumor Cell Lysis by Activated Human Natural Killer Cells, Is a Novel Member of the Immunoglobulin Superfamily. Journal of Experimental Medicine, 1999, 189, 787-796.	8.5	396
59	The leukocyte Ig-like receptor (LIR)-1 for the cytomegalovirus UL18 protein displays a broad specificity for different HLA class I alleles: analysis of LIR-1+ NK cell clones. International Immunology, 1999, 11, 29-35.	4.0	98
60	Linker for Activation of T Cells (LAT), a Novel Immunohistochemical Marker for T Cells, NK Cells, Mast Cells, and Megakaryocytes. American Journal of Pathology, 1999, 154, 1037-1046.	3.8	46
61	FUNCTION AND SPECIFICITY OF HUMAN NATURAL KILLER CELL RECEPTORS. International Journal of Immunogenetics, 1997, 24, 455-468.	1.2	7
62	Basic Fibroblast Growth Factorâ€“Induced Angiogenic Phenotype in Mouse Endothelium. Arteriosclerosis, Thrombosis, and Vascular Biology, 1997, 17, 454-464.	2.4	108
63	Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx. British Journal of Cancer, 1996, 74, 1168-1174.	6.4	18
64	CD94 functions as a natural killer cell inhibitory receptor for different HLA class I alleles: identification of the inhibitory form of CD94 by the use of novel monoclonal antibodies. European Journal of Immunology, 1996, 26, 2487-2492.	2.9	130